Why Perfect B Is Evaluating AOD 9604: Our Clinical Perspective We began our internal evaluation of AOD 9604 in response to a consistent pattern we were seeing with patients in our South Florida practice: people who had experienced meaningful fat loss on GLP-1 medications, then plateaued or discontinued due to side effects, and were looking for a next option
Loren Pickart discovered the significant regenerative benefits of Copper Peptide in the 1970s
The candidate previously demonstrated promising weight loss outcomes in Phase 2 trials, and its progression into late-stage testing underscores the competitive momentum building in this high-growth therapeutic category In January 2024, Zealand Pharma and Boehringer Ingelheim announced positive Phase 2 results for BI 456906, a long-acting GLP-1/glucagon dual agonist, in obese individuals
25 10 3 cells were added in the upper chamber of the Boyden apparatus
The manufacturer doesnt guarantee specific timelines
BPC-157 (Body Protection Compound 157) is a fifteen amino acid synthetic peptide derived from a protein in human gastric juice